Ratutrelvir: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies 14% 1 50 Improvement, Studies, Patients Relative Risk RCTs 14% 1 50 Early 14% 1 50 Ratutrelvir for COVID-19 c19early.org January 2026 Favorsratutrelvir Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Dokukina (RCT) 14% 0.86 [0.76-0.97] no recov. 32 (n) 18 (n) OT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.014 Early treatment 14% 0.86 [0.76-0.97] 32 (n) 18 (n) 14% lower risk All studies 14% 0.86 [0.76-0.97] 32 (n) 18 (n) 14% lower risk 1 ratutrelvir COVID-19 study c19early.org January 2026 Tau​2 = 0.00, I​2 = 0.0%, p = 0.014 Effect extraction pre-specified(most serious outcome) 1 OT: comparison with other treatment Favors ratutrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Dokukina (RCT) 14% 0.86 [0.76-0.97] no recov. 32 (n) 18 (n) OT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.014 Early treatment 14% 0.86 [0.76-0.97] 32 (n) 18 (n) 14% lower risk All studies 14% 0.86 [0.76-0.97] 32 (n) 18 (n) 14% lower risk 1 ratutrelvir COVID-19 recovery result c19early.org January 2026 Tau​2 = 0.00, I​2 = 0.0%, p = 0.014 1 OT: comparison with other treatment Favors ratutrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Dokukina (RCT) 14% 0.86 [0.76-0.97] no recov. 32 (n) 18 (n) OT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.014 Early treatment 14% 0.86 [0.76-0.97] 32 (n) 18 (n) 14% lower risk All studies 14% 0.86 [0.76-0.97] 32 (n) 18 (n) 14% lower risk 1 ratutrelvir COVID-19 Randomized Controlled Trial c19early.org January 2026 Tau​2 = 0.00, I​2 = 0.0%, p = 0.014 Effect extraction pre-specified(most serious outcome) 1 OT: comparison with other treatment Favors ratutrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Dokukina (RCT) 14% 0.86 [0.76-0.97] no recov. 32 (n) 18 (n) OT​1 Improvement, RR [CI] Treatment Control Ratutrelvir COVID-19 outcomes c19early.org January 2026 1 OT: comparison with other treatment Favors ratutrelvir Favors control